NASDAQ:IMMU - Immunomedics Stock Price, Price Target & More

Immunomedics trades on the NASDAQ under the ticker symbol "IMMU."

Immunomedics, Inc. (NASDAQ:IMMU) issued its quarterly earnings data on Wednesday, May, 9th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by $0.06. The biopharmaceutical company had revenue of $0.50 million for the quarter, compared to analyst estimates of $4.27 million. Immunomedics's quarterly revenue was down 61.5% on a year-over-year basis. View Immunomedics' Earnings History.

4 equities research analysts have issued twelve-month target prices for Immunomedics' stock. Their forecasts range from $15.00 to $53.00. On average, they anticipate Immunomedics' stock price to reach $31.50 in the next twelve months. This suggests a possible upside of 24.0% from the stock's current price. View Analyst Ratings for Immunomedics.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunomedics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Immunomedics saw a drop in short interest during the month of June. As of June 15th, there was short interest totalling 24,537,779 shares, a drop of 12.2% from the May 31st total of 27,938,918 shares. Based on an average daily trading volume, of 4,391,738 shares, the short-interest ratio is presently 5.6 days. Currently, 17.0% of the shares of the company are sold short. View Immunomedics' Current Options Chain.

Some companies that are related to Immunomedics include IPSEN S A/S (IPSEY), Neogen (NEOG), Myriad Genetics (MYGN), Quidel (QDEL), Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), Lantheus (LNTH), Quotient (QTNT), Oxford Immunotec Global (OXFD), Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), Riot Blockchain (RIOT), Vermillion (VRML) and ImmuCell (ICCC).

News headlines about IMMU stock have been trending somewhat positive on Tuesday, according to Accern Sentiment. The research group identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Immunomedics earned a news sentiment score of 0.08 on Accern's scale. They also assigned headlines about the biopharmaceutical company an impact score of 45.35 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Immunomedics' stock is owned by a number of of retail and institutional investors. Top institutional investors include SEATTLE GENETICS INC (4.90%). Company insiders that own Immunomedics stock include Behzad Aghazadeh, Brian A Markison, Cynthia L Goldenberg, David M Goldenberg, Don C Stark, Mary E Paetzold and Venbio Select Advisor Llc. View Institutional Ownership Trends for Immunomedics.

Shares of IMMU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of IMMU stock can currently be purchased for approximately $25.40.

Immunomedics has a market capitalization of $4.28 billion and generates $3.09 million in revenue each year. The biopharmaceutical company earns $-153,200,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis. Immunomedics employs 138 workers across the globe.

Immunomedics' mailing address is 300 AMERICAN RD, MORRIS PLAINS NJ, 07950. The biopharmaceutical company can be reached via phone at 973-605-8200 or via email at [email protected]